Cholestasis: Clinical Trials

50 trials for Cholestasis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

50 completed. 50 Phase 2, 6 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 250Completed 50
Phase 16Completed 6
Phase 36Completed 6

Follow Cholestasis: new trials by email Literature Review of Cholestasis trials Research Report on Cholestasis

Trials (filtered) newest first · largest first

All 50 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
K-808 (Dose A), K-808 (Dose B), Placebo - Primary Biliary Cholangitis
Phase 2CompletedKowa Research Institute, Inc.462024-02-072026-10-07
Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis
Remaxa, enteric-coated tablets, Remaxol, Placebo - Cholestasis, Intrahepatic
Phase 2 / Phase 3CompletedPOLYSAN Scientific & Technological Pharmaceutical Company3282023-05-272025-04-29
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
golexanolone, Placebo - Primary Biliary Cholangitis (PBC)
Phase 1 / Phase 2CompletedUmecrine Cognition AB2072023-04-142026-10-16
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
EP547, Placebo - Pruritus
Phase 2CompletedEscient Pharmaceuticals, Inc622022-10-062025-07-31
Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis
ASC42 5 mg, ASC42 10 mg, ASC42 15 mg - Primary Biliary Cholangitis
Phase 2CompletedGannex Pharma Co., Ltd.982022-04-062024-09-27
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo - Primary Biliary Cholangitis
Phase 2 / Phase 3CompletedZydus Therapeutics Inc.1962022-04-012026-09-17
Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg - Primary Biliary Cholangitis
Phase 2CompletedIntercept Pharmaceuticals722022-03-212026-07-16
A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Setanaxib, Placebo - Primary Biliary Cholangitis, Liver Stiffness
Phase 2CompletedCalliditas Therapeutics Suisse SA762022-02-142025-04-24
Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis
CNP-104, Placebo - Primary Biliary Cholangitis
Phase 1 / Phase 2CompletedCOUR Pharmaceutical Development Company, Inc.422022-01-252026-03-10
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
Maralixibat - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome
Phase 2CompletedMirum Pharmaceuticals, Inc.272021-09-092026-06-02
Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
HTD1801 (BUDCA) - Primary Biliary Cholangitis, Primary Biliary Cirrhosis
Phase 2CompletedHighTide Therapeutics (Hong Kong) Limited242021-05-272026-08-25
Combination Antiretroviral Therapy (cART) for PBC
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF), Raltegravir, Placebo Oral Capsule [CEBOCAP] - Primary Biliary Cholangitis
Phase 2CompletedUniversity of Alberta372021-03-012024-02-16
Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Biliary Atresia
Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation - Primary Biliary Cirrhosis
Phase 1 / Phase 2CompletedVinmec Research Institute of Stem Cell and Gene Technology202019-08-102024-06-06
Needle-Knife Fistulotomy Vs. Standard Cannulation Trial
Needle Knife Fistulotomy, standard biliary cannulation - Biliary Obstruction Due to Common Bile Duct Stone, Malignant Bile Duct Obstruction
Phase 1 / Phase 2CompletedThomas Jefferson University1862019-01-312024-11-19
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis
EDP-305 1 mg, EDP-305 2.5 mg, Placebo - Primary Biliary Cholangitis
Phase 2CompletedEnanta Pharmaceuticals, Inc682017-12-272021-05-18
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
Saroglitazar magnesium 2 mg, Saroglitazar magnesium 4 mg, Placebo Oral Tablet - Primary Biliary Cirrhosis
Phase 2CompletedZydus Therapeutics Inc.372017-08-182024-09-19
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
GKT137831, Placebo oral capsule - Primary Biliary Cirrhosis
Phase 2CompletedCalliditas Therapeutics AB1112017-06-262022-06-29
Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid
Elafibranor 80 mg, Elafibranor 120 mg, Placebo - Primary Biliary Cholangitis (PBC)
Phase 2CompletedGenfit452017-04-052019-09-24
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
Placebo, GSK2330672 - Cholestasis
Phase 2CompletedGlaxoSmithKline1472017-01-112021-05-04
Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
Autologous BMMC transplantation - Liver Cirrhosis, Biliary
Phase 2CompletedVinmec Research Institute of Stem Cell and Gene Technology172017-01-022024-06-04

Showing 20 of 50. Sign in to see all of them.

Narrower conditions

Liver Cirrhosis, Biliary (33)  ·  Alagille Syndrome (6)  ·  Pruritus (5)  ·  Cholestasis, Intrahepatic (3)  ·  Short Bowel Syndrome (3)  ·  Bile Duct Diseases (2)  ·  Biliary Atresia (2)  ·  Biliary Tract Diseases (2)  ·  Cholangitis (2)  ·  Cholestasis, progressive familial intrahepatic 1 (2)  ·  Fatigue (2)  ·  Liver Cirrhosis (2)  ·  Liver Diseases (2)  ·  Carcinoma, Hepatocellular (1)

Broader conditions

Digestive System Diseases (50)  ·  Bile Duct Diseases (48)  ·  Biliary Tract Diseases (48)  ·  Liver Diseases (41)  ·  Pathological Conditions, Signs and Symptoms (40)  ·  Cholestasis, Intrahepatic (38)  ·  Pathologic Processes (38)  ·  Fibrosis (32)  ·  Liver Cirrhosis (31)  ·  Congenital Abnormalities (9)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9)  ·  Signs and Symptoms (9)  ·  Abnormalities, Multiple (6)  ·  Cardiovascular Abnormalities (6)

Interventions

fish oil triglycerides (5)  ·  maralixibat (5)  ·  Ursodeoxycholic Acid (3)  ·  obeticholic acid (3)  ·  3-((((3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)methyl)amino)pentanedioic acid (2)  ·  Rituximab (2)  ·  aldafermin (2)  ·  saroglitazar (2)  ·  setanaxib (2)  ·  (2-methyl-4-(5-methyl-2-(4-trifluoromethyl-phenyl)-2H-(1,2,3)triazol-4-ylmethylsulfanyl)phenoxy)acetic acid (1)  ·  (R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acid (1)  ·  2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1)  ·  3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1)  ·  Bezafibrate (1)  ·  Ceftriaxone (1)

Sponsors

Mirum Pharmaceuticals, Inc. (8)  ·  Intercept Pharmaceuticals (3)  ·  GlaxoSmithKline (2)  ·  NGM Biopharmaceuticals, Inc (2)  ·  University of Alberta (2)  ·  Vinmec Research Institute of Stem Cell and Gene Technology (2)  ·  Zydus Therapeutics Inc. (2)  ·  Arthur J De Lorimier (1)  ·  COUR Pharmaceutical Development Company, Inc. (1)  ·  Calliditas Therapeutics AB (1)  ·  Calliditas Therapeutics Suisse SA (1)  ·  Conatus Pharmaceuticals Inc. (1)  ·  Enanta Pharmaceuticals, Inc (1)  ·  Escient Pharmaceuticals, Inc (1)  ·  Gannex Pharma Co., Ltd. (1)

Countries

United States (37)  ·  United Kingdom (19)  ·  Canada (17)  ·  Germany (10)  ·  France (9)  ·  Spain (9)  ·  Australia (6)  ·  Belgium (6)  ·  Poland (6)  ·  Italy (5)  ·  Austria (3)  ·  Greece (3)  ·  Israel (3)  ·  Argentina (2)  ·  Hungary (2)

Top investigators

Liem Nguyen (2)  ·  Stephen J Rossi, PharmD (2)  ·  Adrian DiBisceglie, MD (1)  ·  Andre Belous, MD, PhD (1)  ·  Andrew L Mason, MBBS MRCPI (1)  ·  Andrew Mason, MD (1)  ·  Bruce Bacon, MD (1)  ·  Catherine Vincent, MD FRCPC (1)  ·  Christian Weyer, MD (1)  ·  Christopher Bowlus, MD (1)  ·  Christopher L Bowlus, MD (1)  ·  Claudia O. Zein, MD, MSc (1)

Results publications

PMID 42002216, PMID 38780109, PMID 19661785, PMID 21083674, PMID 23201707, PMID 25543678, PMID 27431238, PMID 28187915, PMID 29790196, PMID 32059815, PMID 33038344, PMID 33484775, PMID 33769355, PMID 34487750, PMID 34695449, PMID 34755627, PMID 35287722, PMID 35367282, PMID 35507739, PMID 36096175, PMID 36267872, PMID 36343847, PMID 36809195, PMID 36852705, PMID 37183520, PMID 37953500, PMID 38862718, PMID 39969430, PMID 40439725, PMID 40745549, PMID 40907882

NIH funding

2016 (3), 2015 (1)